Sara Nayeem, M.D. is Executive Vice President, Investments at Enavate Sciences. She works closely with Jim Boylan on portfolio strategy and is instrumental in the origination, evaluation and selection of Enavate investments. She also supports portfolio companies on strategic growth, governance, partnerships and fundraising, and other long-term planning initiatives.

Sara has 20 years of experience in biotech investing and advisory services. She most recently served as Partner at Avoro Ventures, a biopharma venture fund she helped launch in 2021. Previously she was a Partner at New Enterprise Associates, Inc. (NEA), where she spent 12 years as part of the biopharma investing group. Over her investing career, Sara has played a key diligence and management role in 27 investments, from which there have been 11 IPOs and 10 acquisitions with upfront payments exceeding $16 billion. Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on mergers, acquisitions and financing transactions. She began her career as an Investment Banking Analyst at Morgan Stanley. Sara has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration. She serves on the boards of the New England Venture Capital Association, No Patient Left Behind, and Incubate Coalition, and on the Advisory Board for The Blavatnik Fund for Innovation at Yale.

Sara earned her A.B. in Biology from Harvard College and concurrent M.D./MBA degrees from Yale University.

Return to Team